Singapore – March 17, 2025 – Next Level Genomics Pte Ltd, a specialized genomics service provider, is pleased to announce its certification for providing cutting-edge genomics technologies, including CosMx™ SMI and GeoMx™ DSP from Bruker Spatial Technologies (formerly Nanostring), as well as advanced sequencing platforms including PacBio’s Revio™ and Oxford Nanopore Technologies’ PromethION-24.
This milestone underscores Next Level Genomics’ ongoing commitment to delivering state-of-the-art genomic solutions to researchers and organizations globally. Next level Genomics is also participating in the College of American Pathologists (CAP) Proficiency Testing scheme for NGS.
“These certifications formally validate the company’s existing capabilities and expertise in providing high-quality, precise, and comprehensive genomic insights for various research and clinical applications.” said Gregor Kent, CEO at Next Level Genomics. “We are particularly proud of recent achievements, such as capturing over 1.24 million cells from a single slide on the CosMx™ Human 6K Discovery Panel; generating more than 126 GB of HiFi data from single Revio™ whole human genome samples using PacBio’s new SPRQ chemistry; and integrating ONT’s adaptive sampling technology to enable efficient target enrichment and depletion during sequencing.”
Next Level Genomics specializes in advanced genomics services, including spatial multiomics with Bruker’s NanoString CosMx SMI and GeoMx DSP, high-throughput long-read sequencing from PacBio’s Revio™platform, and versatile sequencing solutions from ONT. These cutting-edge technologies position Next Level Genomics at the forefront of genomic research and discovery.
Contact: +65-6304-3003
Email: [email protected]
